Episurf Medical’s board today announced that its Board of Directors has appointed Pål Ryfors CEO, effective immediately.
Executive Chairman, Dennis Stripe says: “Mr. Ryfors has demonstrated leadership and the responsibilities of the CEO role, during the last 5 months as the acting CEO. Pål understands the importance of strategic responsiveness that a young company needs to compete.” Mr. Stripe added; “We, the Board of Episurf Medical, feel the talent of Pal and his ability to understand the orthopaedic industry along with his ability to build relationships within the Episurf team, make him the ideal candidate"
Pål Ryfors joined Episurf Medical as CFO in December 2015, a position he has held since then. In addition, Pål Ryfors has been acting CEO since January 2017. Pål worked in the financial industry during 2006 – 2015, most recently as CFO of Marginalen Bank.
Pål says: "I am very grateful about this opportunity. Episurf Medical is a highly exciting company with a world leading technology. Since its inception, Episurf Medical has established itself as an innovative force in the orthopaedic industry, and with continued delivery of strong clinical evidence, the opportunities for accelerated growth are approaching. It is a fantastic opportunity to work at a company that aims at being the world leader in its niche, and Episurf Medical is doing just that. The level of ambition is high, and I look forward towards being part of this journey”.
Pål Ryfors is born in 1983 and a board member of Aros Kapital. Pål has a B. Sc. in Business and Administration from Gothenburg School of Economics.
The company also announces that Veronica Wallin is appointed CFO of Episurf Medical and will be a member of the company’s management team. Veronica has been Head of Finance since August 2016 and previously, had the same position at ApoEx.
For more information, please contact:
Dennis Stripe, Chairman of the Board of Directors
Tel: +46 (0)8 612 00 20
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16.25 CET on 2 June 2017.